CRDL Cardiol Therapeutics Inc.

$1.80

Cardiol Therapeutics Inc. (CRDL) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +19.2% since its last earnings release on August 12, 2026.

Cardiol Therapeutics Beat Consensus Estimates
Wednesday, August 12, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · Before Open
Earnings Whisper
-
vs ($0.08)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.71

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

Sector

Healthcare

Industry

Drug Manufacturers/Other